Search Results for “FDA” – Page 187 – media

US regulators wave through Pfizer’s leukaemia drug

Pfizer’s Besponsa has been approved by the US Food and Drug Administration (FDA). It's the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
- Source: pharmatimes
- 1,029
- August 21, 2017
ALL antibody Company Insight FDA New Approvals
VentureMed raises $15m in Series B

Vascular focused device developer VentureMed said today it raised $15 million in a Series B round.
- Source: massdevice
- 497
- August 16, 2017
Company Insight Market Views medical device peripheral artery Series
Kite begins EU trial of CAR–T therapy

Kite Pharma has begun treating the first EU patients with its investigational CAR–T candidate, axicabtagene ciloleucel (axi-cel), in the safety expansion cohort of the ZUMA-1 trial.
- Source: pharmatimes
- 821
- August 10, 2017
CAR–T Clinical Trials Company Insight EU FDA
CombiMatrix, Skyline Medical, Victory Square Technologies

The merger and acquisition information of CombiMatrix, Skyline Medical and Victory Square Technologies.
- Source: medicaldevices-network.com
- 383
- August 7, 2017
Company Insight M&A Market Views
Roche reports strong performance in the first half of 2017

Commenting on the Group’s results, Roche CEO Severin Schwan said: “In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions showed strong performance, very much driven by new product launches. Particularly pleasing is the very successful launch of Ocrevus for the treatment of two forms of multiple sclerosis. Based on our half-year performance, we raised the outlook for the full-year to mid-single digit sales growth.”
- Source: www.roche.com
- 505
- August 4, 2017
Company Insight
GSK delivers further progress in Q2 and sets out new priorities for the Group

GSK delivers further progress in Q2 and sets out new priorities for the Group
- Source: www.gsk.com/
- 372
- August 4, 2017
Company Insight
Johnson & Johnson Reports 2017 Second-Quarter Results

New Brunswick, N.J. (July 18, 2017) – Johnson & Johnson (NYSE: JNJ) today announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016. Operational sales results increased 2.9% and the negative impact of currency was 1.0%. Domestic sales increased 1.6%. International sales increased 2.3%, reflecting operational growth of 4.4% and a negative currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%.*
- Source: www.jnj.com
- 593
- August 4, 2017
Company Insight
Sciex launches new LC-MS clinical diagnostic system

US-based Sciex Diagnostics has launched a new fully integrated LC-MS solution, Sciex Topaz System, for use in clinical diagnostics.
- Source: medicaldevice-network.com
- 547
- August 2, 2017
Company Insight diagnostic Sciex
Emergent secures $23m to develop new auto-injector for US’ DoD

US-based life sciences firm Emergent BioSolutions has secured around $23m for the development of a new multi-drug auto-injector to deliver nerve agent antidote.
- Source: medicaldevice-network.com
- 423
- August 2, 2017
antidote FDA Market Views
Takeda and BioSurfaces to develop new medical devices for GI indications

Japan's Takeda Pharmaceutical Company has signed an agreement with US-based nanotechnology provider BioSurfaces to develop new therapeutic devices to treat gastrointestinal (GI) diseases.
- Source: Medicaldevice-network
- 421
- July 28, 2017
Company Insight gastrointestinal nanofibrous New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.